Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society
SEATTLE, Sept. 5, 2019 /PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that it will present four scientific abstracts at the 19th Congress of the International Headache Society (IHC) being held September 5 – 8, 2019 in Dublin, Ireland.
"Our growing body of evidence supports the potential of INP104 to be a transformative new therapy for acute migraine. INP104 utilizes our sophisticated and proprietary new device technology to deliver optimal doses of dihydroergotamine (DHE) to the vascular-rich upper nasal cavity, resulting in peak drug concentration levels that may be more effective for patients," said Stephen B. Shrewsbury, M.D., Chief Medical Officer of Impel NeuroPharma. "Importantly, because INP104 is designed to deliver a reduced dose of DHE compared to FDA-approved and investigational products in development, patients may be able to reap the established efficacy benefits of DHE, without the undesired side effects that are typically experienced with delivery to the lower nasal space."
The meeting abstracts will be published in digital format within the official abstract book of the meeting which can be accessed on the IHC meeting website at http://www.ihc2019.com. Presented abstracts will also be published in Cephalalgia.
Four Impel-sponsored posters, including new findings from the I-BEAM patient experience and satisfaction survey, will be presented on Saturday, September 7 between 2:45-3:45 pm IST:
These data that will be presented at the meeting to support the ongoing "STOP-301 Trial" (Safety and Tolerability of POD-DHE), a Phase 3, open-label safety and tolerability trial evaluating long-term (24/52 week), intermittent use of INP104 for the treatment of acute migraine.
About Acute Migraine
About Impel NeuroPharma
Impel's product candidates are delivered via its proprietary Precision Olfactory Delivery, or POD®, technology which targets the richly vascularized upper nasal cavity with the goal of achieving enhanced bioavailability of therapeutic molecules.
IMPEL, POD and the IMPEL Logo are trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com/.
About Precision Olfactory Delivery or POD® Devices
View original content to download multimedia:http://www.prnewswire.com/news-releases/impel-neuropharma-to-present-data-from-inp104-clinical-program-at-the-19th-congress-of-the-international-headache-society-300912746.html
SOURCE Impel NeuroPharma